Navigation Links
Metabolex Appoints Donald Hill as Chief Financial Officer
Date:4/14/2008

HAYWARD, Calif., April 14 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions. Mr. Hill joins Metabolex following more than 20 years in finance and corporate development management roles at Merck & Co., Inc., most recently as Assistant Treasurer, Global Capital Markets.

"The appointment of Don expands the depth of our already strong management team," said President and Chief Executive Officer Harold Van Wart, Ph.D. "Don's experience as a leader in a well respected, financially sophisticated pharmaceutical company, his experience in business development, and his strong analytical skills and strategic financial vision will be critical for us as we expand our product pipeline and move our clinical product candidates towards commercialization. With the company's four clinical product candidates and active discovery and preclinical development programs, Don's skills in financial planning and strategic product development will be invaluable."

Mr. Hill is a Chartered Financial Analyst (CFA), and holds a B.A. from the University of California, Berkeley and a Masters degree from the Sloan School of Management at the Massachusetts Institute of Technology.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has recently completed a Phase 2/3 trial; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which has just commenced a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Appoints New Independent Auditor
2. Indivumed Appoints Annette Kassen as Vice President Clinical Research
3. ADVENTRX Appoints Vice President of Manufacturing
4. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
5. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
6. Observant LLC Appoints Two New Directors to the Senior Management Team
7. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
8. Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
9. IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
10. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
11. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand program ... in Volunteer Experience from US2020. , US2020’s mission is to change the trajectory ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Phoenix, Arizona (PRWEB) , ... October 09, 2017 ... ... of Kindred, a four-tiered line of medical marijuana products targeting the needs of ... production and packaging of Kindred takes place in Phoenix, Arizona. , As operators ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):